Characterizing Cannabinoid CB2 Receptor Ligands Using DiscoveRx PathHunter™ β-Arrestin Assay

被引：49

作者：

Mcguinness, Debra ^{[1
]}

Malikzay, Asra ^{[1
]}

Visconti, Richard ^{[1
]}

Lin, Karen ^{[1
]}

Bayne, Marvin ^{[1
]}

Monsma, Frederick ^{[1
]}

Lunn, Charles A. ^{[1
]}

机构：

[1] Schering Plough Corp, Res Inst, New Lead Discovery, Kenilworth, NJ 07033 USA

来源：

JOURNAL OF BIOMOLECULAR SCREENING | 2009年 / 14卷 / 01期

关键词：

cannabinoid CB2 receptor; beta-arrestin; complementation; signal transduction; BONE MASS; CHEMOTAXIS; ACTIVATION; CELLS; AGONISTS; 2-ARACHIDONOYLGLYCEROL; MODULATION;

D O I：

10.1177/1087057108327329

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

The authors have characterized a set of cannabinoid CB2 receptor ligands, including triaryl bis sulfone inverse agonists, in a cell-based receptor/beta-arrestin interaction assay (DiscoveRx PathHunter (TM)). The results were compared with results using a competitive ligand binding assay, and with effects on forskolin-stimulated cAMP levels (PerkinElmer LANCE (TM)). The authors show good correlation between the 3 assay systems tested, with the beta-arrestin protein complementation assay exhibiting a more robust signal than the cAMP assay for cannabinoid CB2 agonists. Further assay validation shows that DiscoveRx PathHunter (TM) HEK293 CB2 beta-arrestin assay can be carried out from cryopreserved cell suspensions, eliminating variations caused by the need for multiple cell pools during live cell screening campaigns. These results, and the authors' results evaluating a test set of random library compounds, validate the use of ligand-induced interaction between the human cannabinoid CB2 receptor and beta-arrestin as an appropriate and valuable screening platform for compounds specific for the cannabinoid CB2 receptor. (Journal of Biomolecular Screening 2009:49-58)

引用

页码：49 / 58

页数：10

共 30 条

[1] Novel cannabinoid receptors [J].

Brown, A. J. .

BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (05) :567-575

[2] Targeting cannabinoid agonists for inflammatory and neuropathic pain [J].

Cheng, Yuan ;

Hitchcock, Stephen A. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) :951-965

[3] Temporal variation in CB2R levels following T lymphocyte activation:: Evidence that cannabinoids modulate CXCL12-induced chemotaxis [J].

Coopman, Karen ;

Smith, Laura D. ;

Wright, Karen L. ;

Ward, Stephen G. .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2007, 7 (03) :360-371

[4] β-arrestins and cell signaling [J].

DeWire, Scott M. ;

Ahn, Seungkirl ;

Lefkowitz, Robert J. ;

Shenoy, Sudha K. .

ANNUAL REVIEW OF PHYSIOLOGY, 2007, 69 :483-510

[5] A β-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis [J].

Ge, L ;

Ly, Y ;

Hollenberg, M ;

DeFea, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (36) :34418-34426

[6] Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes [J].

Ghosh, Sharmistha ;

Preet, Anju ;

Groopman, Jerome E. ;

Ganju, Ramesh K. .

MOLECULAR IMMUNOLOGY, 2006, 43 (14) :2169-2179

[7] Agonist selective regulation of g proteins by cannabinoid CB1 and CB2 receptors [J].

Glass, M ;

Northup, JK .

MOLECULAR PHARMACOLOGY, 1999, 56 (06) :1362-1369

[8] Molecular dissection of G protein preference using Gsα chimeras reveals novel ligand signaling of GPCRs [J].

Hsu, Shih-Han ;

Luo, Ching-Wei .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 293 (04) :E1021-E1029

[9] Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors [J].

Idris, AI ;

Hof, RJV ;

Greig, IR ;

Ridge, SA ;

Baker, D ;

Ross, RA ;

Ralston, SH .

NATURE MEDICINE, 2005, 11 (07) :774-779

[10]

Jordà MA, 2002, BLOOD, V99, P2786

← 1 2 3 →